Strategies to limit immune-activation in HIV patients

References

• Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov 2;382(9903):1525–1533.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.
   PubMed Web of Science ®Google Scholar
• Iwasaki A. Innate immune recognition of HIV-1. Immunity. 2012;37(3):389–398.
   PubMed Web of Science ®Google Scholar
• Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505(7484):509–514.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Pantazis N, Martin GE, et al. Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection. PLoS Pathog. 2016 Jul 14;12(7):e1005661.
   PubMed Web of Science ®Google Scholar
• Banga R, Procopio FA, Noto A, et al. PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat Med. 2016 Jul;22(7):754–761.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200(6):749–759.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008;112(7):2826–2835.
   PubMed Web of Science ®Google Scholar
• Page EE, Greathead L, Metcalf R, et al. Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infection. J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):227–235.
   PubMed Web of Science ®Google Scholar
• Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 2010;6(4):e1000852.
   PubMed Web of Science ®Google Scholar
• Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol. 2008;46(2):757–758.
   PubMed Web of Science ®Google Scholar
• Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014;10(2):e1003829.
   PubMed Web of Science ®Google Scholar
• McCune JM, Napolitano LA, Grant RM, et al. Increased production of IL-7 accompanies HIV-1- mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7(1):73–79.
   PubMed Web of Science ®Google Scholar
• Catalfamo M, Di Mascio M, Hu Z, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci USA. 2008;105(50):19851–19856.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51–F58.
   PubMed Web of Science ®Google Scholar
• Mynarcik DC, McNurlan MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr. 2000;25(4):312–321.
   PubMed Web of Science ®Google Scholar
• Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29(4):463.
   PubMed Web of Science ®Google Scholar
• Group ISS Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27; 373(9): 795–807
   Google Scholar
• Srinivasula S, Lempicki RA, Adelsberger JW, et al. Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. Blood. 2011;118:262–270.
   PubMed Web of Science ®Google Scholar
• Soria A, Trabattoni D, Squillace N, et al. Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trial. PLoS One. 2015 Feb 11;10(2):e0117118.
   Web of Science ®Google Scholar
• Piconi S, Trabattoni D, Gori A, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS. 2010;24:1991–2000.
   PubMed Web of Science ®Google Scholar
• Roger PM, Breittmayer JP, Durant J, et al. Early CD4(+) T cell recovery in human immunodeficiency virus-infected patients receiving effective therapy is related to a downregulation of apoptosis and not to proliferation. J Infect Dis. 2002;185:463–470.
   PubMed Web of Science ®Google Scholar
• Hatano H, Yukl SA, Ferre AL, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 2013;9(10):e1003691.
   PubMed Web of Science ®Google Scholar
• Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55(1):126–136.
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7:8.
   Web of Science ®Google Scholar
• Llibre JM, Buzon MJ, Massanella M, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther. 2012;17(2):355–364.
   PubMed Web of Science ®Google Scholar
• Vallejo A, Gutierrez C, Hernandez-Novoa B, et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS. 2012;26(15):1885–1894.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2014;66(2):140–147.
   PubMed Web of Science ®Google Scholar
• Hatano H, Strain MC, Scherzer R, et al. Increase in 2-LTR circles and decrease in D-dimer after raltegravir intensification in treated HIV-infected patients: a randomized, placebo-controlled trial. J Infect Dis. 2013;208:1436–1442.
   PubMed Web of Science ®Google Scholar
• Buzón MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16(4):460–465.
   PubMed Web of Science ®Google Scholar
• Cuzin L, Trabelsi S, Delobel P, et al. Maraviroc intensification of stable antiviral therapy in HIV-1- infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J Acquir Immune Defic Syndr. 2012;61(5):557–564.
   PubMed Web of Science ®Google Scholar
• Wilkin TJ, Lalama CM, McKinnon J, et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4(+) T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012;206(4):534–542.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013;121(23):4635–4646.
   PubMed Web of Science ®Google Scholar
• Serrano-Villar S, Sainz T, Ma ZM, et al. Effects of combined CCR5/integrase inhibitors-based regimen on mucosal immunity in HIV-infected patients naïve to antiretroviral therapy: a pilot randomized trial. PLoS Pathog. 2016 Jan 21;12(1):e1005381.
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Chomont N, Fletcher JL, et al. Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. J Virus Erad. 2015;1(2):116–122.
   PubMed Web of Science ®Google Scholar
• Baroncelli S, Galluzzo CM, Pirillo MF, et al. Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with < 50copies/ml HIV-1 RNA. J Clin Virol. 2009 Dec;46(4):367–370.
   PubMed Web of Science ®Google Scholar
• Hatano H, Jain V, Hunt PW, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis. 2013;208:50–56.
   PubMed Web of Science ®Google Scholar
• Klatt NR, Chomont N, Douek DC, et al. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013;254:326–342.
   PubMed Web of Science ®Google Scholar
• Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood. 2013;121:4321–4329.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345:169–174.
   PubMed Web of Science ®Google Scholar
• Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr Opin HIV AIDS. 2016 Mar;11(2):234–241.
   PubMed Web of Science ®Google Scholar
• Martinez-Picado J, Deeks SG. Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS. 2016 Jul;11(4):417–423.
   PubMed Web of Science ®Google Scholar
• Fromentin R, Bakeman W, Lawani MB, et al. CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog. 2016 Jul 14;12(7):e1005761.
   PubMed Web of Science ®Google Scholar
• Procopio FA, Fromentin R, Kulpa DA, et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. EBioMedicine. 2015 Jun 27;2(8):874–883.
   PubMed Web of Science ®Google Scholar
• Vandergeeten C, Fromentin R, Merlini E, et al. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol. 2014 Nov;88(21):12385–12396.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Redondo R, Fryer HR, Bedford T, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016 Feb 4;530(7588):51–56.
   PubMed Web of Science ®Google Scholar
• Huang Y, Hoque MT, Jenabian M-A, et al. Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site. J Antimicrob Chemother. 2016 Jul;71(7):1954–1965.
   PubMed Web of Science ®Google Scholar
• Madruga JR, Cassetti I, Suleiman JMAH, et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials. 2007;8(6):381–390.
   PubMed Web of Science ®Google Scholar
• Ucciferri C, Falasca K, Vignale F, et al. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol. 2013;85(5):755–759.
   PubMed Web of Science ®Google Scholar
• Mondi A, Fabbiani M, Ciccarelli N, et al. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. J Antimicrob Chemother. 2015;70(6):1843–1849.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77–85.
   PubMed Web of Science ®Google Scholar
• MacInnes A, Lazzarin A, Di Perri G, et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials. 2011;12(1):24–36.
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002 May;109(9):1125–1131.
   PubMed Web of Science ®Google Scholar
• Bianchi S, Grimaldi D, Bigazzi R. Statins and lipid-lowering strategies in cardiorenal patients. Contrib Nephrol. 2011;171:143–150.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Tuñón J, Martín-Ventura JL, et al. Antiinflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63(1):12–23.
   PubMed Web of Science ®Google Scholar
• Elahi S, Weiss RH, Merani S. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS. 2016 Jan;30(2):171–183.
   PubMed Web of Science ®Google Scholar
• Calza L, Vanino E, Salvadori C, et al. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV infected patients. HIV Clin Trials. 2014;15:1–13.
   PubMed Web of Science ®Google Scholar
• Aslangul E, Fellahi S, Assoumou LK, et al. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS. 2011;25:1128–1131.
   PubMed Web of Science ®Google Scholar
• Nakanjako D, Ssinabulya I, Nabatanzi R, et al. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health. 2015 Mar;20(3):380–390.
   PubMed Web of Science ®Google Scholar
• Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011 Mar 15;203(6):756–764.
   PubMed Web of Science ®Google Scholar
• Hileman CO, Turner R, Funderburg NT, et al. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS. 2016 Jan 2;30(1):65–73.
   PubMed Web of Science ®Google Scholar
• Nou E, Lu MT, Looby SE, et al. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. AIDS. 2016 Feb 20;30(4):583–590.
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015 Apr 1; 68(4):396–404. .
   PubMed Web of Science ®Google Scholar
• Erlandson KM, O’Riordan M, Labbato D, et al. Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;65:290–298.
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Boucher M, Sattar A, et al. Rosuvastatin decreases intestinal fatty acid binding protein (I-FABP), but does not alter zonulin or lipopolysaccharide binding protein (LBP) levels, in HIV-infected subjects on antiretroviral therapy. Pathog Immun. 2016 Spring;1(1):118–128.
   PubMedGoogle Scholar
• Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860.
   PubMed Web of Science ®Google Scholar
• O’Brien M, Montenont E, Hu L, et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr. 2013;63(3):280–288.
   PubMed Web of Science ®Google Scholar
• Liu SF, Wang H, Li Z-J, et al. Aspirin induces lytic cytotoxicity in Epstein-Barr virus–positive cells. Eur J Pharmacol. 2008;589(1–3):8–13.
   PubMed Web of Science ®Google Scholar
• Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 2000;96(7):2537–2542.
   PubMed Web of Science ®Google Scholar
• Lei X, Bai Z, Ye F, et al. Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat Cell Biol. 2010;12(2):193–199.
   PubMed Web of Science ®Google Scholar
• Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA. 1982;79(1):175–178.
   PubMed Web of Science ®Google Scholar
• Sperber K, Quraishi H, Kalb TH, et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol. 1993;20(5):803–808.
   PubMed Web of Science ®Google Scholar
• Loffler BM, Bohn E, Hesse B, et al. Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. Biochim Biophys Acta. 1985;835(3):448–455.
   PubMed Web of Science ®Google Scholar
• Cohen SN, Yielding KL. Spectrophotometric studies of the interaction of chloroquine with deoxyribonucleic acid. J Biol Chem. 1965;240:3123–3131.
   PubMed Web of Science ®Google Scholar
• Lesiak A, Narbutt J, Sysa-Jedrzejowska A, et al. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus. 2010;19(6):683–688.
   PubMed Web of Science ®Google Scholar
• Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA – evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006;2(9):458–459.
   PubMedGoogle Scholar
• Fesen MR, Kohn KW, Leteurtre F, et al. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci USA. 1993;90:2399–2403.
   PubMed Web of Science ®Google Scholar
• Jiang MC, Lin JK, Chen SS. Inhibition of HIV-1 Tat transactivation by quinacrine and chloroquine. Biochem Biophys Res Commun. 1996;226:1–7.
   PubMed Web of Science ®Google Scholar
• Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011;118(12):3263–3272.
   PubMed Web of Science ®Google Scholar
• Routy J-P, Angel JB, Patel M, et al. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015;16(1):48–56.
   PubMed Web of Science ®Google Scholar
• He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 1997;385:645–649.
   PubMed Web of Science ®Google Scholar
• Kusao I, Shiramizu B, Liang C-Y, et al. Cognitive performance related to HIV-1-infected monocytes. J Neuropsychiatry Clin Neurosci. 2012;24:71–80.
   PubMed Web of Science ®Google Scholar
• Westhorpe CLV, Maisa A, Spelman T, et al. Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals. Immunol Cell Biol. 2014;92:133–138.
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood. 2012;120:4599–4608.
   PubMed Web of Science ®Google Scholar
• Baker JV, Hullsiek KH, Singh A, et al. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS. 2013;28:831–840.
   Web of Science ®Google Scholar
• Brown KC, Patterson KB, Malone SA, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis. 2011;203:1484–1490.
   PubMed Web of Science ®Google Scholar
• Scopelliti F, Pollicita M, Ceccherini-Silberstein F, et al. Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. Antiviral Res. 2011;92:255–261.
   PubMed Web of Science ®Google Scholar
• Marsden MD, Avancena P, Kitchen CM, et al. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother. 2011;55:3696–3702.
   PubMed Web of Science ®Google Scholar
• Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199(8):1177–1185.
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115(2):161–167.
   PubMed Web of Science ®Google Scholar
• Zevin AS, McKinnon L, Burgener A, et al. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS. 2015;11:182–190.
   Web of Science ®Google Scholar
• Dillon SM, Lee EJ1, Kotter CV, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014;7:983–994.
   PubMed Web of Science ®Google Scholar
• Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013;5:193ra191.
   Web of Science ®Google Scholar
• Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014;10:e1003829.
   PubMed Web of Science ®Google Scholar
• Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol. 2008;46:757–758.
   PubMed Web of Science ®Google Scholar
• Dagenais-Lussier X, Aounallah M, Mehraj V, et al. Kynurenine reduces memory CD4 T-cell survival by interfering with interleukin-2 signaling early during HIV-1 infection. J Virol. 2016 Aug 12;90(17):7967–7979.
   PubMed Web of Science ®Google Scholar
• Lee SA, Mefford JA, Huang Y, et al. Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. AIDS. 2016 Jul 17;30(11):1807–1815.
   PubMed Web of Science ®Google Scholar
• Boasso A, Vaccari M, Hryniewicz A, et al. Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection. J Virol. 2007 Nov 12;81(21):11593–11603.
   PubMed Web of Science ®Google Scholar
• Routy J-P, Mehraj V, Vyboh K, et al. Clinical relevance of kynurenine pathway in HIV/AIDS: an immune checkpoint at the crossroads of metabolism and inflammation. AIDS Rev. 2015 Apr–Jun;17(2):96–106.
   PubMed Web of Science ®Google Scholar
• Jenabian M-A, El-Far M, Vyboh K, et al. Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection. J Infect Dis. 2015 Aug 1;212(3):355–366.
   PubMed Web of Science ®Google Scholar
• Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013 Jul 10;5(193):193ra91.
   PubMed Web of Science ®Google Scholar
• Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137(3 Suppl 2):830S–7S.
   PubMed Web of Science ®Google Scholar
• Guggenbichler JP, De Bettignies-Dutz A, Meissner P. Acidic oligosaccharides from natural sources block adherence of Escherichia coli on uroepithelial cells. Pharm Pharmacol Lett. 1997;7:35–38.
   Google Scholar
• Hummelen R, Vos AP, Van’t Land B, et al. Altered host-microbe interaction in HIV: a target for intervention with pro- and prebiotics. Int Rev Immunol. 2010 Oct;29(5):485–513.
   PubMed Web of Science ®Google Scholar
• Kelly P, Todd J, Sianongo S, et al. Susceptibility to intestinal infection and diarrhoea in Zambian adults in relation to HIV status and CD4 count. BMC Gastroenterol. 2009;9:7.
   PubMed Web of Science ®Google Scholar
• Plettenberg A, Stoehr A, Stellbrink H-J, et al. A preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea. Clin Investig. 1993;71(1):42–45.
   PubMedGoogle Scholar
• Gori A, Rizzardini G, Van’t Land B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial. Mucosal Immunol. 2011;4(5):554–563.
   PubMed Web of Science ®Google Scholar
• Cahn P, Ruxrungtham K, Gazzard B, et al. The immunomodulatory nutritional intervention NR100157 reduced CD4(+) T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-Infected persons not receiving antiretroviral therapy (the BITE study). CID. 2013;57:139–146.
   PubMed Web of Science ®Google Scholar
• Byakwaga H, Kelly M, Purcell DFJ, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis. 2011;204(10):1532–1540.
   PubMed Web of Science ®Google Scholar
• Food and Agriculture Organization of the United Nations (FAO). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. Available from: www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf
   Google Scholar
• Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res. 1992;32:141–144.
   PubMed Web of Science ®Google Scholar
• Schlee M, Wehkamp J, Altenhoefer A. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun. 2007;75:2399–2407.
   PubMed Web of Science ®Google Scholar
• Spinler JK, Taweechotipatr M, Rognerud CL, et al. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe. 2008;14:166–171.
   PubMed Web of Science ®Google Scholar
• Heinemann C, Van Hylckama Vlieg JE, Janssen DB, et al. Purification and characterization of a surface-binding protein from Lactobacillus fermentum RC-14 that inhibits adhesion of Enterococcus faecalis 1131. FEMS Microbiol Lett. 2000;190:177–180.
   PubMed Web of Science ®Google Scholar
• Alak JI, Wolf BW, Mdurvwa EG. Effect of Lactobacillus reuteri on intestinal resistance to Cryptosporidium parvum infection in a murine model of acquired immunodeficiency syndrome. J Infect Dis. 1997;175:218–221.
   PubMed Web of Science ®Google Scholar
• Su Y, Zang B, Su L. CD4 detected from Lactobacillus helps understand the interaction between Lactobacillus and HIV. Microbiol Res. 2013 Jun 12;168(5):273–277.
   PubMed Web of Science ®Google Scholar
• González-Hernández LA, Jave-Suarez L-S, Fafutis-Morris M, et al. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial. Nutr J. 2012 Oct;11(1):90.
   PubMed Web of Science ®Google Scholar
• Hemsworth JC, Hekmat SHekmid GReid S, Reid G. Micronutrient supplemented probiotic yogurt for HIV-infected adults taking HAART in London, Canada. Gut Microbes. 2012;3(5):414–419.
   PubMed Web of Science ®Google Scholar
• d’Ettorre G, Ceccarelli G, Giustini N, et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the “Probio-HIV” clinical trial. PLoS One. 2015;10(9):e0137200.
   PubMed Web of Science ®Google Scholar
• Kim CJ, Walmsley SL, Raboud JM, et al. Can probiotics reduce inflammation and enhance gut immune health in people living with HIV: study designs for the probiotic Visbiome for inflammation and translocation (PROOV IT) pilot trials. HIV Clin Trials. 2016 Jul;17(4):147–157.
   PubMed Web of Science ®Google Scholar
• Hensley-McBain T1, Zevin AS, Manuzak J, et al. Effects of fecal microbial transplantation on microbiome and immunity in simian immunodeficiency virus-infected macaques. J Virol. 2016 Apr 29;90(10):4981–4989.
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, et al. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:2272–2279.
   PubMed Web of Science ®Google Scholar
• Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005;149:820–825.
   PubMed Web of Science ®Google Scholar
• Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014 Nov 15;210(10):1549–1554.
   PubMed Web of Science ®Google Scholar
• Kristoff J,Haret-Richter G, et al. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest. 2014 Jun; 124 (6): 2802–2806
   PubMed Web of Science ®Google Scholar